STAAR Surgical (NASDAQ:STAA) Receives Average Rating of “Hold” from Analysts

Shares of STAAR Surgical (NASDAQ:STAA) have earned an average rating of “Hold” from the ten research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $25.29.

A number of analysts have recently commented on STAA shares. Stifel Nicolaus lowered their target price on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, February 12th. StockNews.com downgraded STAAR Surgical from a “hold” rating to a “sell” rating in a report on Thursday, February 13th. Jefferies Financial Group cut shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Mizuho cut shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $45.00 to $17.00 in a research note on Wednesday, February 12th. Finally, BTIG Research downgraded shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 12th.

STAAR Surgical Stock Down 1.1 %

STAAR Surgical stock opened at $17.72 on Friday. The stock has a 50-day moving average price of $19.87 and a 200 day moving average price of $25.70. The company has a market capitalization of $874.04 million, a price-to-earnings ratio of -43.22 and a beta of 0.66. STAAR Surgical has a 52 week low of $13.50 and a 52 week high of $52.68.

Insider Buying and Selling

In other news, major shareholder Broadwood Partners, L.P. bought 8,221 shares of STAAR Surgical stock in a transaction on Thursday, January 16th. The shares were bought at an average cost of $21.50 per share, with a total value of $176,751.50. Following the completion of the purchase, the insider now directly owns 10,878,007 shares of the company’s stock, valued at approximately $233,877,150.50. This trade represents a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders have purchased 1,036,187 shares of company stock worth $17,239,548. 1.00% of the stock is owned by corporate insiders.

Institutional Trading of STAAR Surgical

Institutional investors have recently made changes to their positions in the company. Quarry LP purchased a new stake in STAAR Surgical in the 3rd quarter valued at about $50,000. Quest Partners LLC acquired a new stake in shares of STAAR Surgical during the third quarter valued at about $128,000. KLP Kapitalforvaltning AS purchased a new stake in shares of STAAR Surgical in the 4th quarter valued at approximately $180,000. Larson Financial Group LLC lifted its holdings in shares of STAAR Surgical by 78.3% in the 3rd quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier’s stock worth $181,000 after acquiring an additional 2,135 shares during the last quarter. Finally, Bridgefront Capital LLC lifted its holdings in shares of STAAR Surgical by 27.2% in the 4th quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock worth $262,000 after acquiring an additional 2,306 shares during the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.